True At-Home Diagnostics: Reshaping Infectious Disease with Nathalya Mamane, CEO of Anywhere Dx
Show notes
In this episode of Diagnosing Dx, I’m joined by Nathalya Mamane, Co-Founder and CEO at Anywhere Dx.
Nathalya shares the origin story behind Anywhere Dx and how a personal pain point led her to build a diagnostics company focused on bringing molecular testing into the home. We explore why the current standard of care for infectious disease testing is still too slow, too expensive, and too dependent on centralised infrastructure, and what COVID revealed about how people actually want to engage with diagnostics when access and convenience matter most.
We also discuss what it really takes to build an at-home diagnostic that can scale, from creating a fully disposable, instrument-free molecular platform to navigating regulatory validation, strategic partnerships, and the commercial realities of diagnostics today. This is a practical conversation about access, simplicity, and what it means to design diagnostics for real consumer use rather than idealised clinical workflows.
Key takeaways:
🔹 Why most at-home diagnostics still fall short on simplicity and scalability
🔹 How Anywhere Dx is approaching low-cost, disposable molecular testing
🔹 Why strategic partnerships are critical for commercialising diagnostics effectively
🔹 What COVID revealed about consumer behaviour and diagnostic access
🔹 Why funding, validation, and regulatory strategy remain major hurdles in diagnostics
Guest:
Nathalya Mamane
LinkedIn: www.linkedin.com/in/nathalya-mamane/
Learn more about Anywhere Dx: https://www.anywhere.health/
Host:
David Filby
LinkedIn: www.linkedin.com/in/davidfilby/
Learn more about Elevra Consulting: https://elevraconsulting.com/
Key chapters:
01:48 Nathalya’s journey into diagnostics
03:38 The birth of Anywhere Dx
07:54 Technology and product overview
10:45 Market need, strep, and the impact on healthcare systems
14:44 Science behind the product
19:41 Development status and funding challenges
26:19 Commercial strategy, partnerships, and regulatory pathway
30:18 Investor sentiment and market outlook
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.